Viatris’ Global Leadership in Advancing Access and Responsible Action Against AMR
Viatris uses a comprehensive strategy to help address antimicrobial resistance (AMR). This includes expanding access to more than 90 antimicrobial products and working closely with partners such as the AMR Industry Alliance (AMRIA), where the company is both a founding member and an active board participant.
In 2024, the UN General Assembly hosted a high-level meeting of world leaders aimed at strengthening global political commitment to tackling AMR, culminating in the adoption of the Political Declaration on AMR. As part of the broader dialogue leading up to this milestone, Viatris, Foreign Policy magazine, and other key stakeholders co-organized the simulation event “A World Without Antibiotics – Confronting the Global AMR Challenge.”
The exercise brought together experts from government, industry, and civil society to explore practical solutions to prevent the severe consequences of escalating AMR. During the event, Viatris and AMRIA urged UN member states to guarantee universal, equitable, affordable, and sustainable access to high-quality antibiotics and diagnostic tools—and to take action on the environmental factors that contribute to AMR.
As co-chair of AMRIA’s Access Working Group, Viatris led the creation of the AMRIA Equitable and Responsible Access Roadmap, released in February 2024. Developed through a collaborative, evidence-driven process, the roadmap serves as a global policy framework aimed at improving access to safe, effective antibiotics. It identifies major obstacles—such as regulatory barriers, unreliable demand forecasting, and procurement limitations—and provides guidance on how to overcome them.
Advancing Scalable Solutions in the Fight Against AMR
In 2024, Viatris also partnered with BBC Storyworks to spotlight PLATINEA (PLATform for INnovation of Existing Antibiotics), an innovative Swedish collaboration involving universities, healthcare providers, public agencies, insurers, regulators, and the pharmaceutical industry. The campaign helped raise global awareness of PLATINEA’s model and encouraged discussions about replicating its approach in other regions as part of the worldwide effort to combat AMR.
Responsible Manufacturing to Mitigate AMR
Viatris remains deeply committed to responsible antimicrobial manufacturing and is a founding member of AMRIA, actively participating in its Manufacturing Working Group. In addition to expanding access to antimicrobials and supporting their appropriate use, the company adheres to AMRIA’s Antibiotic Manufacturing Standard across its own operations and is working to implement this standard throughout its external supply network.
In 2024, as part of a five-year plan, Viatris continued evaluating its major antibiotic suppliers on their alignment with the AMRIA Manufacturing Standard. By the end of the year, the company had completed 84% of the scheduled audits.
In 2024, the UN General Assembly hosted a high-level meeting of world leaders aimed at strengthening global political commitment to tackling AMR, culminating in the adoption of the Political Declaration on AMR. As part of the broader dialogue leading up to this milestone, Viatris, Foreign Policy magazine, and other key stakeholders co-organized the simulation event “A World Without Antibiotics – Confronting the Global AMR Challenge.”
The exercise brought together experts from government, industry, and civil society to explore practical solutions to prevent the severe consequences of escalating AMR. During the event, Viatris and AMRIA urged UN member states to guarantee universal, equitable, affordable, and sustainable access to high-quality antibiotics and diagnostic tools—and to take action on the environmental factors that contribute to AMR.
As co-chair of AMRIA’s Access Working Group, Viatris led the creation of the AMRIA Equitable and Responsible Access Roadmap, released in February 2024. Developed through a collaborative, evidence-driven process, the roadmap serves as a global policy framework aimed at improving access to safe, effective antibiotics. It identifies major obstacles—such as regulatory barriers, unreliable demand forecasting, and procurement limitations—and provides guidance on how to overcome them.
Advancing Scalable Solutions in the Fight Against AMR
In 2024, Viatris also partnered with BBC Storyworks to spotlight PLATINEA (PLATform for INnovation of Existing Antibiotics), an innovative Swedish collaboration involving universities, healthcare providers, public agencies, insurers, regulators, and the pharmaceutical industry. The campaign helped raise global awareness of PLATINEA’s model and encouraged discussions about replicating its approach in other regions as part of the worldwide effort to combat AMR.
Responsible Manufacturing to Mitigate AMR
Viatris remains deeply committed to responsible antimicrobial manufacturing and is a founding member of AMRIA, actively participating in its Manufacturing Working Group. In addition to expanding access to antimicrobials and supporting their appropriate use, the company adheres to AMRIA’s Antibiotic Manufacturing Standard across its own operations and is working to implement this standard throughout its external supply network.
In 2024, as part of a five-year plan, Viatris continued evaluating its major antibiotic suppliers on their alignment with the AMRIA Manufacturing Standard. By the end of the year, the company had completed 84% of the scheduled audits.
Companies